Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44154   clinical trials with a EudraCT protocol, of which   7326   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

    Summary
    EudraCT number
    		 2017-004134-29
    Trial protocol
    		 GB   DE   IE   ES   DK   PL  
    Global end of trial date
    09 Sep 2020

    Results information
    Results version number
    		 v2(current)
    This version publication date
    13 Feb 2022
    First version publication date
    25 Mar 2021
    Other versions
    		 v1
    Version creation reason

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    VX17-659-105
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT03447262
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue, Boston, Massachusetts, United States,
    Public contact
    Vertex Pharmaceuticals Incorporated, Medical Monitor, +1 617-341-6777, medicalinfo@vrtx.com
    Scientific contact
    Vertex Pharmaceuticals Incorporated, Medical Monitor, +1 617-341-6777, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    		 EMEA-002191-PIP02-17
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    27 Oct 2020
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    09 Sep 2020
    Global end of trial reached?
    Yes
    Global end of trial date
    09 Sep 2020
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    13 Jul 2018
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    		 Safety
    Long term follow-up duration
    		 1 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 49
    Country: Number of subjects enrolled
    Canada: 9
    Country: Number of subjects enrolled
    Israel: 19
    Country: Number of subjects enrolled
    United States: 262
    Country: Number of subjects enrolled
    Denmark: 4
    Country: Number of subjects enrolled
    Germany: 57
    Country: Number of subjects enrolled
    Ireland: 23
    Country: Number of subjects enrolled
    Poland: 2
    Country: Number of subjects enrolled
    Spain: 19
    Country: Number of subjects enrolled
    Switzerland: 7
    Country: Number of subjects enrolled
    United Kingdom: 33
    Worldwide total number of subjects
    484
    EEA total number of subjects
    105
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    119
    Adults (18-64 years)
    365
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 This study was conducted in CF subjects aged 12 years or older who participated in parent studies VX17-659-102 (659-102; NCT03447249) or VX17-659-103 (659-103; NCT03460990). Eligible subjects from the parent studies were enrolled in the current study VX17-659-105 (659-105).

    Period 1
    Period 1 title
    Triple Combination Treatment Period (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Arm title
    		 VX-659/TEZ/IVA TC
    Arm description
    		 Subjects from parent studies 659-102 or 659-103 were administered VX-659 240 milligrams (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the TC treatment period for up to 96 weeks in the current study 659-105.
    Arm type
    		 Experimental

    Investigational medicinal product name
    VX-659/TEZ/IVA
    Investigational medicinal product code
    VX-659/VX-661/VX-770
    Other name
    VX-659/Tezacaftor/Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-659/TEZ/IVA fixed-dose combination qd in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA qd in the evening.

    Number of subjects in period 1 [1]
    		VX-659/TEZ/IVA TC
    Started
    481
    Completed
    2
    Not completed
    479
         Death
    2
         Other
    4
         Adverse event
    7
         Study termination by sponsor
    455
         Withdrawal of consent (not due to AE)
    2
         Commercial drug is available for subject
    9
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: The total of 484 subjects were enrolled from the parent studies. Out of which, 3 subjects were enrolled but never dosed in this study. Therefore, 481 subjects are included in subject disposition and baseline sections.

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    VX-659/TEZ/IVA TC
    Reporting group description
    		 Subjects from parent studies 659-102 or 659-103 were administered VX-659 240 milligrams (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the TC treatment period for up to 96 weeks in the current study 659-105.

    Reporting group values
    		 VX-659/TEZ/IVA TC Total
    Number of subjects
    		 481 481
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    		 26.9 ( 9.7 ) -
    Gender categorical
    Units: Subjects
        Female
    		 219 219
        Male
    		 262 262
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    		 14 14
        Not Hispanic or Latino
    		 462 462
        Unknown or Not Reported
    		 5 5
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    		 0 0
        Asian
    		 0 0
        Native Hawaiian or Other Pacific Islander
    		 0 0
        Black or African American
    		 3 3
        White
    		 474 474
        More than one race
    		 4 4
        Unknown or Not Reported
    		 0 0

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    VX-659/TEZ/IVA TC
    Reporting group description
    		 Subjects from parent studies 659-102 or 659-103 were administered VX-659 240 milligrams (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the TC treatment period for up to 96 weeks in the current study 659-105.

    Subject analysis set title
    VX-659/TEZ/IVA TC: Parent Study 659-102
    Subject analysis set type
    		 Full analysis
    Subject analysis set description
    Subjects who either received placebo (matched to VX-659/TEZ/IVA) or VX-659/TEZ/IVA in the parent study 659-102 were administered VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the TC treatment period for up to 96 weeks in the current study 659-105.

    Subject analysis set title
    VX-659/TEZ/IVA TC: Parent Study 659-103
    Subject analysis set type
    		 Full analysis
    Subject analysis set description
    Subjects who either received TEZ/IVA or VX-659/TEZ/IVA in the parent study 659-103 were administered VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the TC treatment period for up to 96 weeks in the current study 659-105.

    Primary: Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    		 Close Top of page
    End point title
    		 Safety and Tolerability as Assessed by Number of Subjects With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [1]
    End point description
    Open label safety set (OL-SS) included all subjects who received at least 1 dose of study drug in the current study 659-105.
    End point type
    Primary
    End point timeframe
    From Day 1 up to 28 Days After Last Dose of Study Drug or to the Completion of Study Participation Date, Whichever Occurs First in the Current Study 659-105 (up to Week 100)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned. No statistical comparisons were planned for this endpoint.
    End point values
    		 VX-659/TEZ/IVA TC
    Number of subjects analysed
    481
    Units: subjects
        Subjects With AEs
    470
        Subjects With SAEs
    99
    No statistical analyses for this end point

    Secondary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for Subjects From the Parent Study 659-102

    		 Close Top of page
    End point title
    		 Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for Subjects From the Parent Study 659-102
    End point description
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The analysis was planned to be reported separately for Placebo - VX-659/TEZ/IVA category (subjects who received placebo in the parent study 659-102 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-102 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. Open label full analysis set (OL-FAS) included all rolled over subjects from the parent study 659-102 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    371
    Units: percentage points
    arithmetic mean (standard deviation)
        Placebo - VX-659/TEZ/IVA (n=183)
    14.2 ( 7.8 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=188)
    10.3 ( 9.3 )
    No statistical analyses for this end point

    Secondary: Absolute Change in ppFEV1 for Subjects From the Parent Study 659-103

    		 Close Top of page
    End point title
    		 Absolute Change in ppFEV1 for Subjects From the Parent Study 659-103
    End point description
    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. The analysis was planned to be reported separately for TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659-TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-103 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-103 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    110
    Units: percentage points
    arithmetic mean (standard deviation)
        TEZ/IVA - VX-659/TEZ/IVA (n=56)
    15.1 ( 11.9 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=54)
    11.5 ( 9.8 )
    No statistical analyses for this end point

    Secondary: Absolute Change in Sweat Chloride (SwCl) for Subjects From the Parent Study 659-102

    		 Close Top of page
    End point title
    		 Absolute Change in Sweat Chloride (SwCl) for Subjects From the Parent Study 659-102
    End point description
    Sweat samples were collected using an approved collection device. The analysis was planned to be reported separately for Placebo - VX-659/TEZ/IVA category (subjects who received placebo in the parent study 659-102 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-102 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-102 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 24 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    371
    Units: millimole per liter (mmol/L)
    arithmetic mean (standard deviation)
        Placebo - VX-659/TEZ/IVA (n=183)
    -48.9 ( 20.4 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=188)
    -49.7 ( 20.1 )
    No statistical analyses for this end point

    Secondary: Absolute Change in SwCl for Subjects From the Parent Study 659-103

    		 Close Top of page
    End point title
    		 Absolute Change in SwCl for Subjects From the Parent Study 659-103
    End point description
    Sweat samples were collected using an approved collection device. The analysis was planned to be reported separately for TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659-TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/ IVA in both the parent study 659-103 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-103 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 24 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    110
    Units: mmol/L
    arithmetic mean (standard deviation)
        TEZ-IVA - VX-659/TEZ/IVA (n=56)
    -45.7 ( 16.8 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=54)
    -53.5 ( 16.2 )
    No statistical analyses for this end point

    Secondary: Number of Pulmonary Exacerbations (PEx) for Subjects From the Parent Study 659-102

    		 Close Top of page
    End point title
    		 Number of Pulmonary Exacerbations (PEx) for Subjects From the Parent Study 659-102
    End point description
    PEx was defined as treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for at least 4 sinopulmonary signs/symptoms. The analysis was planned to be reported separately for Placebo - VX-659/TEZ/IVA category (subjects who received placebo in the parent study 659-102 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in the parent study 659-102 or/and VX-659/TEZ/IVA in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline except for Placebo - VX-659/TEZ/IVA category, for which the baseline was defined as study 659-105 baseline. The cumulative efficacy set included subjects who received at least one dose of study drug in the parent study and/or received at least one dose of study drug in the current study 659-105. Here, "n" signifies subjects evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline up to Week 96 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    375
    Units: PEx events
        Placebo - VX-659/TEZ/IVA (n=183)
    60
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=192)
    84
    No statistical analyses for this end point

    Secondary: Number of PEx for Subjects From the Parent Study 659-103

    		 Close Top of page
    End point title
    		 Number of PEx for Subjects From the Parent Study 659-103
    End point description
    PEx was defined as treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for at least 4 sinopulmonary signs/symptoms. The analysis was planned to be reported for the overall subjects from the parent study 659-103 that is combined for TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in the parent study 659-103 or/and VX-659/TEZ/IVA in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline except for TEZ/IVA - VX-659/TEZ/IVA category, for which the baseline was defined as study 659-105 baseline. The cumulative efficacy set included subjects who received at least one dose of study drug in the parent study 659-103 and/or received at least one dose of study drug in the current study 659-105.
    End point type
    Secondary
    End point timeframe
    From Baseline up to Week 96 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    110
    Units: PEx events
    39
    No statistical analyses for this end point

    Secondary: Number of Subjects With at Least one PEx for Subjects From the Parent Study 659-102

    		 Close Top of page
    End point title
    		 Number of Subjects With at Least one PEx for Subjects From the Parent Study 659-102
    End point description
    Time-to-first-PEx data were planned to be estimated using Kaplan-Meier (KM) method. However, because way less than 50% subjects had event, time-to-first event data were not estimable. Instead, number of subjects with at least one PEx event was assessed and reported separately for Placebo - VX-659/TEZ/IVA category (subjects received placebo in parent study 659-102 and VX-659/TEZ/IVA in current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects received VX-659/TEZ/IVA in parent study 659-102 or/and VX-659/TEZ/IVA in current study 659-105). Baseline was defined as parent study baseline except for Placebo - VX-659/TEZ/IVA category, for which baseline was defined as study 659-105 baseline. The cumulative TC efficacy set for PEx analysis included all subjects who were randomized to VX-659/TEZ/IVA arm and received at least one dose of study drug during the parent study 659-102 and/or current study 659-105. Here, "n" signifies subjects evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline up to Week 96 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    375
    Units: subjects
        Placebo - VX-659/TEZ/IVA (n=183)
    43
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=192)
    52
    No statistical analyses for this end point

    Secondary: Number of Subjects With at Least one PEx for Subjects From the Parent Study 659-103

    		 Close Top of page
    End point title
    		 Number of Subjects With at Least one PEx for Subjects From the Parent Study 659-103
    End point description
    Time-to-first-PEx data were planned to be estimated using the KM method. However, because way less than 50% of subjects had events, median time-to-first-event data were not estimable. Instead, the number of subjects with at least one PEx event was assessed and reported for all subjects from the parent study 659-103, that is combined for those in the TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659-TEZ/IVA in the current study 659-105) and the VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in the parent study 659-103 or/and in the current study 659-105). Baseline was defined as parent study baseline except for TEZ/IVA - VX-659/TEZ/IVA category, for which baseline was defined as study 659-105 baseline. The cumulative TC efficacy set for PEx analysis included subjects who were randomized to VX-659/TEZ/IVA arm and received at least one dose of study drug during the parent study and/or study 659-105.
    End point type
    Secondary
    End point timeframe
    From Baseline up to Week 96 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    110
    Units: subjects
    28
    No statistical analyses for this end point

    Secondary: Absolute Change in Body Mass Index (BMI) for Subjects From the Parent Study 659-102

    		 Close Top of page
    End point title
    		 Absolute Change in Body Mass Index (BMI) for Subjects From the Parent Study 659-102
    End point description
    BMI was defined as weight in kilograms (kg) divided by squared height in meters (m^2). The analysis was planned to be reported separately for Placebo - VX-659/TEZ/IVA category (subjects who received placebo in the parent study 659-102 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-102 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-102 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    371
    Units: kilogram per meter square (kg/m^2)
    arithmetic mean (standard deviation)
        Placebo - VX-659/TEZ/IVA (n=183)
    1.55 ( 1.35 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=188)
    1.43 ( 1.94 )
    No statistical analyses for this end point

    Secondary: Absolute Change in BMI for Subjects From the Parent Study 659-103

    		 Close Top of page
    End point title
    		 Absolute Change in BMI for Subjects From the Parent Study 659-103
    End point description
    BMI was defined as weight in kg divided by squared height in meters (m^2). The analysis was planned to be reported separately for TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659-TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-103 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-103 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    110
    Units: kg/m^2
    arithmetic mean (standard deviation)
        TEZ/IVA - VX-659/TEZ/IVA (n=56)
    1.16 ( 1.68 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=54)
    0.90 ( 1.52 )
    No statistical analyses for this end point

    Secondary: Absolute Change in BMI Z-score for Subjects From the Parent Study 659-102 (Subjects <=20 Years Old at Parent Study Baseline)

    		 Close Top of page
    End point title
    		 Absolute Change in BMI Z-score for Subjects From the Parent Study 659-102 (Subjects <=20 Years Old at Parent Study Baseline)
    End point description
    The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard. The analysis was planned to be reported separately for Placebo - VX-659/TEZ/IVA category (subjects who received placebo in the parent study 659-102 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/ IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-102 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-102 who were <=20 years old at parent study baseline and received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 60 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    114
    Units: z-score
    arithmetic mean (standard deviation)
        Placebo - VX-659/TEZ/IVA (n=57)
    0.22 ( 0.59 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=57)
    0.10 ( 0.44 )
    No statistical analyses for this end point

    Secondary: Absolute Change in BMI Z-score for Subjects From The Parent Study 659-103 (Subjects <=20 Years Old at Parent Study Baseline)

    		 Close Top of page
    End point title
    		 Absolute Change in BMI Z-score for Subjects From The Parent Study 659-103 (Subjects <=20 Years Old at Parent Study Baseline)
    End point description
    The analysis was planned to be reported separately for TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659-TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-103 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-103 who were <=20 years old at parent study baseline and received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category and "99999" signifies "not available" as the summary statistics were no longer applicable for due to less than 20 subjects in each category (pre-specified criteria in analysis plan). Therefore, no BMI z-score efficacy data is available for both categories.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 60 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    30
    Units: z-score
    arithmetic mean (standard deviation)
        TEZ/IVA - VX-659/TEZ/IVA (n=16)
    99999 ( 99999 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=14)
    99999 ( 99999 )
    No statistical analyses for this end point

    Secondary: Absolute Change in Body Weight for Subjects From the Parent Study 659-102

    		 Close Top of page
    End point title
    		 Absolute Change in Body Weight for Subjects From the Parent Study 659-102
    End point description
    The analysis was planned to be reported separately for Placebo - VX-659/TEZ/IVA category (subjects who received placebo in the parent study 659-102 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/ TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-102 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-102 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    371
    Units: kg
    arithmetic mean (standard deviation)
        Placebo - VX-659/TEZ/IVA (n=183)
    4.8 ( 4.4 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=188)
    4.3 ( 5.6 )
    No statistical analyses for this end point

    Secondary: Absolute Change in Body Weight for Subjects From the Parent Study 659-103

    		 Close Top of page
    End point title
    		 Absolute Change in Body Weight for Subjects From the Parent Study 659-103
    End point description
    The analysis was planned to be reported separately for TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659-TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/ IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-103 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-103 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    110
    Units: kg
    arithmetic mean (standard deviation)
        TEZ/IVA - VX-659/TEZ/IVA (n=56)
    3.7 ( 4.9 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=54)
    3.2 ( 5.0 )
    No statistical analyses for this end point

    Secondary: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for Subjects From the Parent Study 659-102

    		 Close Top of page
    End point title
    		 Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for Subjects From the Parent Study 659-102
    End point description
    The CFQ-R is a validated subject-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. The analysis was planned to be reported separately for Placebo - VX-659/TEZ/IVA category (subjects who received placebo in the parent study 659-102 and VX-659/TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-102 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-102 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-102
    Number of subjects analysed
    371
    Units: units on a scale
    arithmetic mean (standard deviation)
        Placebo - VX-659/TEZ/IVA (n=183)
    16.7 ( 18.7 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=188)
    19.7 ( 17.4 )
    No statistical analyses for this end point

    Secondary: Absolute Change in CFQ-R Respiratory Domain Score for Subjects From the Parent Study 659-103

    		 Close Top of page
    End point title
    		 Absolute Change in CFQ-R Respiratory Domain Score for Subjects From the Parent Study 659-103
    End point description
    The CFQ-R is a validated subject-reported outcome measuring health-related quality of life for subjects with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. The analysis was planned to be reported separately for TEZ/IVA - VX-659/TEZ/IVA category (subjects who received TEZ/IVA in the parent study 659-103 and VX-659-TEZ/IVA in the current study 659-105) and VX-659/TEZ/IVA - VX-659/TEZ/IVA category (subjects who received VX-659/TEZ/IVA in both the parent study 659-103 and in the current study 659-105) as pre-specified in analysis plan. Baseline was defined as the parent study baseline. OL-FAS included all rolled over subjects from the parent study 659-103 who received at least 1 dose of study drug in the current study 659-105. Here, "n" signifies subjects who were evaluable for the specified category.
    End point type
    Secondary
    End point timeframe
    From Baseline at Week 72 (Study 659-105)
    End point values
    		 VX-659/TEZ/IVA TC: Parent Study 659-103
    Number of subjects analysed
    110
    Units: units on a scale
    arithmetic mean (standard deviation)
        TEZ/IVA - VX-659/TEZ/IVA (n=56)
    17.1 ( 18.2 )
        VX-659/TEZ/IVA - VX-659/TEZ/IVA (n=54)
    16.9 ( 17.3 )
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From Day 1 up to 28 Days After Last Dose of Study Drug or to the Completion of Study Participation Date, Whichever Occurs First in the Current Study 659-105 (up to Week 100)
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    23.0
    Reporting groups
    Reporting group title
    VX-659/TEZ/IVA TC
    Reporting group description
    		 Subjects from parent studies 659-102 or 659-103 were administered VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the TC treatment period for up to 96 weeks in the current study 659-105.

    Serious adverse events
    		 VX-659/TEZ/IVA TC
    Total subjects affected by serious adverse events
         subjects affected / exposed
    99 / 481 (20.58%)
         number of deaths (all causes)
    2
         number of deaths resulting from adverse events
    General disorders and administration site conditions
    Generalised oedema
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Systemic inflammatory response syndrome
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Immune system disorders
    Anaphylactic reaction
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Granulomatous pneumonitis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Haemoptysis
         subjects affected / exposed
    5 / 481 (1.04%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Increased bronchial secretion
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pleuritic pain
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Delirium
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Breathing-related sleep disorder
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Anxiety
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Suicidal ideation
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Product issues
    Device leakage
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Investigations
    Aspartate aminotransferase increased
         subjects affected / exposed
    4 / 481 (0.83%)
         occurrences causally related to treatment / all
    4 / 5
         deaths causally related to treatment / all
    0 / 0
    Alanine aminotransferase increased
         subjects affected / exposed
    4 / 481 (0.83%)
         occurrences causally related to treatment / all
    4 / 5
         deaths causally related to treatment / all
    0 / 0
    Pulmonary function test decreased
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    2 / 481 (0.42%)
         occurrences causally related to treatment / all
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Alcohol poisoning
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Contusion
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Craniocerebral injury
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Forearm fracture
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Toxicity to various agents
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Stoma site extravasation
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Intentional overdose
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Congenital, familial and genetic disorders
    Cystic fibrosis related diabetes
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Restrictive cardiomyopathy
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac failure acute
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Nervous system disorders
    Syncope
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Seizure
         subjects affected / exposed
    2 / 481 (0.42%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Abdominal pain
         subjects affected / exposed
    3 / 481 (0.62%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Constipation
         subjects affected / exposed
    2 / 481 (0.42%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Distal intestinal obstruction syndrome
         subjects affected / exposed
    6 / 481 (1.25%)
         occurrences causally related to treatment / all
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    Duodenitis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastritis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Mechanical ileus
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Cholangitis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Biliary colic
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bile duct stone
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Autoimmune hepatitis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis
         subjects affected / exposed
    2 / 481 (0.42%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis chronic
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Hydronephrosis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    3 / 481 (0.62%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Pelvi-ureteric obstruction
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    Compartment syndrome
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Infections and infestations
    Bacterial disease carrier
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bronchitis bacterial
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    H1N1 influenza
         subjects affected / exposed
    2 / 481 (0.42%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Mastoiditis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Lower respiratory tract infection bacterial
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    Influenza
         subjects affected / exposed
    4 / 481 (0.83%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    40 / 481 (8.32%)
         occurrences causally related to treatment / all
    0 / 53
         deaths causally related to treatment / all
    0 / 0
    Medical device site cellulitis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    2 / 481 (0.42%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Pneumonia pseudomonal
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Sepsis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tonsillitis
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular device infection
         subjects affected / exposed
    2 / 481 (0.42%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Diabetes mellitus inadequate control
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diabetes mellitus
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    1 / 481 (0.21%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 VX-659/TEZ/IVA TC
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    446 / 481 (92.72%)
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    43 / 481 (8.94%)
         occurrences all number
    55
    Blood creatine phosphokinase increased
         subjects affected / exposed
    37 / 481 (7.69%)
         occurrences all number
    43
    Aspartate aminotransferase increased
         subjects affected / exposed
    42 / 481 (8.73%)
         occurrences all number
    51
    Nervous system disorders
    Headache
         subjects affected / exposed
    51 / 481 (10.60%)
         occurrences all number
    69
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    31 / 481 (6.44%)
         occurrences all number
    34
    Pyrexia
         subjects affected / exposed
    56 / 481 (11.64%)
         occurrences all number
    64
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    42 / 481 (8.73%)
         occurrences all number
    51
    Vomiting
         subjects affected / exposed
    27 / 481 (5.61%)
         occurrences all number
    33
    Nausea
         subjects affected / exposed
    36 / 481 (7.48%)
         occurrences all number
    46
    Diarrhoea
         subjects affected / exposed
    42 / 481 (8.73%)
         occurrences all number
    47
    Abdominal pain upper
         subjects affected / exposed
    26 / 481 (5.41%)
         occurrences all number
    36
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    126 / 481 (26.20%)
         occurrences all number
    205
    Sinus congestion
         subjects affected / exposed
    27 / 481 (5.61%)
         occurrences all number
    39
    Respiration abnormal
         subjects affected / exposed
    28 / 481 (5.82%)
         occurrences all number
    30
    Rhinorrhoea
         subjects affected / exposed
    40 / 481 (8.32%)
         occurrences all number
    50
    Nasal congestion
         subjects affected / exposed
    53 / 481 (11.02%)
         occurrences all number
    66
    Oropharyngeal pain
         subjects affected / exposed
    80 / 481 (16.63%)
         occurrences all number
    106
    Sputum increased
         subjects affected / exposed
    69 / 481 (14.35%)
         occurrences all number
    90
    Haemoptysis
         subjects affected / exposed
    39 / 481 (8.11%)
         occurrences all number
    57
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    28 / 481 (5.82%)
         occurrences all number
    37
    Infections and infestations
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    149 / 481 (30.98%)
         occurrences all number
    264
    Influenza
         subjects affected / exposed
    40 / 481 (8.32%)
         occurrences all number
    45
    Sinusitis
         subjects affected / exposed
    30 / 481 (6.24%)
         occurrences all number
    45
    Nasopharyngitis
         subjects affected / exposed
    97 / 481 (20.17%)
         occurrences all number
    163
    Upper respiratory tract infection
         subjects affected / exposed
    104 / 481 (21.62%)
         occurrences all number
    178
    Viral upper respiratory tract infection
         subjects affected / exposed
    38 / 481 (7.90%)
         occurrences all number
    53

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    26 Jan 2018
    Amended to add study drug dose and tablet strength. Clarified completion of study participation and study drug interruptions and discontinuation scenarios.
    23 Oct 2018
    Amended to update stopping rules and add clarifications on descriptions for efficacy and pharmacodynamics variables.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA